Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott renal stenting trial

This article was originally published in The Gray Sheet

Executive Summary

Abbott enrolls first patient Sept. 25 in a U.S. trial for its RX Herculink Elite renal stent system. The 50-site HERCULINK single-arm study is expected to enroll 202 patients with renal artery stenosis who have not responded to drug treatment for hypertension by early 2009. Primary follow-up of patients implanted with the cobalt chromium stent will be at nine months, with additional analyses out to three years. CMS is in the process of reconsidering its national coverage policy for renal stenting, in part due to a perceived lack of evidence as to its efficacy (1"The Gray Sheet" July 23, 2007, p. 18)

You may also be interested in...

Medicare Coverage Advisers Split On Renal Artery Stenting

CMS' Medicare Evidence Development Coverage Advisory Committee (MedCAC) could not reach consensus on whether Medicare coverage of angioplasty and stenting to treat renal artery disease should be limited to patients in clinical trials

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts